LC
MLYS icon

Lindbrook Capital’s Mineralys Therapeutics MLYS Stock Holding History

Lindbrook Capital’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$1.64K Buy
+103
New +$1.19K ﹤0.01% 2339

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Lindbrook Capital's MLYS Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Mineralys Therapeutics (MLYS) in Q1 2025: 103 shares worth $1.64K. The stake represents ﹤0.01% of the portfolio and ranks #2339 among its holdings.

149 funds tracked by Wall St. Rank hold MLYS as of Q1 2025.

  • Lindbrook Capital held 103 shares of Mineralys Therapeutics worth $1.64K as of Q1 2025.
  • Mineralys Therapeutics was a new Lindbrook Capital position in Q1 2025.
  • Mineralys Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2339 holding.
  • 149 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.